By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Oragenics, Inc. 

12085 Research Drive

Alachua  Florida  32615  U.S.A.
Phone: 386-418-4018 Fax: 386-462-0875




Company News
U.S. FDA Grants Fast Track Designation For The Development Of Oragenics (OGEN)’ AG013 For Oral Mucositis 11/21/2016 11:54:55 AM
Oragenics (OGEN) Receives Supportive FDA Feedback For Initiating A Phase II Study Protocol For Oral Mucositis Treatment 8/30/2016 11:16:11 AM
Oragenics (OGEN) Announces Receipt Of Payment In Full Under Promissory Note In Connection With Sale Of Consumer Probiotic Business 8/2/2016 9:21:33 AM
Oragenics (OGEN) Announces NYSE MKT Acceptance Of Its Plan Of Compliance 7/19/2016 11:01:18 AM
Oragenics (OGEN) Announces Closing Of $4.667 Million Private Placement 7/1/2016 9:23:46 AM
Oragenics (OGEN) Announces Completion Of Sale Of Consumer Probiotic Business 6/27/2016 10:09:16 AM
Oragenics (OGEN) Announces Entry Into Definitive Agreement To Sell Consumer Probiotic Business 6/23/2016 8:19:09 AM
Oragenics (OGEN) Names a New CEO 6/7/2016 11:09:08 AM
Oragenics, Inc. (OGEN) Announces Notification Of Noncompliance With NYSE MKT Continued Listing Standards 5/16/2016 11:21:16 AM
Oragenics, Inc. (OGEN) Announces Positive Results From Confirmatory Animal Study Of AG013 For Treatment Of Oral Mucositis And Plans To Finalize Phase 2 Clinical Trial Protocol 5/3/2016 9:43:46 AM